Back to Search Results
Study Complete
Sponsor ID
20040202

Study Evaluating Darbepoetin Alfa in Subjects with Chronic Kidney Disease (CKD) Receiving Dialysis

Sponsor ID
20040202
Clinicaltrials.gov ID
NCT00096915
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

The proposed study is designed to test a novel dosing paradigm

that would facilitate the treatment of anemia in CKD patients on dialysis.

Anemic patients on hemo and peritoneal dialysis who have achieved and

maintained target hemoglobin (Hb) on every other week (Q2W) dosing of darbepoetin alfa will have the dosing interval extended to once monthly (QM) dosing.

Additional Study Details

Phase
Phase 3
Product
darbepoetin alfa
Type
Interventional
Masking
None (Open Label)
Enrollment
110
Additional Study Details

Protocol Summary

Primary Outcome Measures

The proportion of subjects on QM darbepoetin alfa dosing maintained with a mean Hb greater than or equal to 11.0 g/dL and less than or equal to 13.0 g/dL during the evaluation phase

Timeframe: entire study

Secondary Outcome Measures

Hb values over the duration of the study

Timeframe: entire study

Darbepoetin alfa doses over the duration of the study

Timeframe: entire study

Frequency and relationship to treatment for adverse events and changes in laboratory parameters and blood pressure

Timeframe: entire study

Study Documents

Study Synopsis
Available Language(s): English
Download Document(s)

Locations

No locations found.
Study Info
Age
18+ years
Condition
  • Kidney Disease
    • Sex
    All
    Trial Dates
    Oct 2004 - Nov 2005
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for > 3 months before enrollment - Clinically stable, in the judgment of the investigator - Mean Hb > 11.0 g/dL (110 g/L) to < 13.0 g/dL (130 g/L) - Transferrin saturation (Tsat) > 19.5% - Serum vitamin B12 and folate levels above the lower limit of the normal range - Receiving stable Q2W IV or SC doses of Aranesp® (darbepoetin alfa). A stable dose is defined as less than or equal to 25% change in dose over the 6-week period immediately prior to enrollment and with no missed doses in this period
    Exclusion Criteria:
    - Scheduled to receive a kidney transplant - Diastolic blood pressure greater than 110 mm Hg or systolic BP greater than 180 mm Hg during screening - Acute myocardial ischemia - Hospitalization for congestive heart failure, myocardial infarction, deep vein thrombosis, stroke or transient ischemic attack within 12 weeks before enrollment - Parathyroid hormone (PTH) level greater than 1500 pg/mL (158.0 pmol/L) - Major surgery within 12 weeks before enrollment (excluding vascular access surgery) - Currently receiving antibiotic therapy for systemic infection - Known positive HIV antibody or positive hepatitis B surface antigen - Clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia - Red blood cell (RBC) transfusions within 8 weeks before enrollment - Androgen therapy within 8 weeks before enrollment - Systemic hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia) - Any disorder that may impact (in the judgment of the investigator) the ability to give informed consent for participation in this study - Pregnant or breast-feeding women - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial - Treatment with an investigational agent or device within 30 days before enrollment or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study